Tamer I. Khayal Sells 15,512 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 15,512 shares of the firm’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total value of $1,403,060.40. Following the completion of the transaction, the insider now owns 25,185 shares in the company, valued at approximately $2,277,983.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $93.95 on Friday. The business’s 50-day moving average price is $82.70 and its 200-day moving average price is $71.76. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $99.63. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of -122.01 and a beta of 1.99. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. During the same period last year, the firm posted ($0.21) earnings per share. The business’s revenue for the quarter was up 158.6% on a year-over-year basis. Equities research analysts forecast that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Oppenheimer lifted their target price on TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Piper Sandler started coverage on TransMedics Group in a research report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 target price on the stock. Finally, Morgan Stanley lifted their target price on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $102.00.

Institutional Trading of TransMedics Group

A number of hedge funds have recently made changes to their positions in the company. Harbour Capital Advisors LLC boosted its stake in shares of TransMedics Group by 1.7% during the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock valued at $627,000 after purchasing an additional 140 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in shares of TransMedics Group by 45.1% during the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock valued at $41,000 after purchasing an additional 169 shares in the last quarter. Belpointe Asset Management LLC boosted its stake in shares of TransMedics Group by 51.6% during the first quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock valued at $42,000 after purchasing an additional 190 shares in the last quarter. RiverPark Advisors LLC lifted its stake in shares of TransMedics Group by 19.5% in the fourth quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock worth $104,000 after acquiring an additional 215 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of TransMedics Group by 2.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,512 shares of the company’s stock worth $896,000 after acquiring an additional 288 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.